


# Cu(I)–NHC-Catalyzed (2 + 3)-Annulation of Tetramic Acids with 2*H*-Azirines: Stereoselective Synthesis of Functionalized Hexahydropyrrolo[3,4-*b*]pyrroles

Nikolai V. Rostovskii, Pavel A. Sakharov, Mikhail S. Novikov,\* Alexander F. Khlebnikov, and Galina L. Starova

Institute of Chemistry, Saint-Petersburg State University, Universitetskii pr. 26, 198504 St. Petersburg, Russia

**S** Supporting Information

**ABSTRACT:** A stereoselective and high-yield synthesis of hexahydropyrrolo[3,4-*b*]pyrroles from tetramic acids and 2*H*-azirines under Cu(I)–NHC catalysis is developed. An unusual N–C2 azirine bond cleavage, initiated by a copper enolate, was rationalized in terms of a free radical reaction mechanism.




Various pyrrolopyrrole compounds are attracting a growing attention due to a wide range of biological activities and useful photophysical and optical properties.<sup>1</sup> The pyrrolo[3,4-*b*]pyrrole core is known to be the basic unit of h5-HT<sub>1D</sub> receptor agonists,<sup>2</sup> which are effective for relieving migraine headache, 5-HT<sub>2C</sub> receptor agonists,<sup>3</sup> applicable for obesity treatment, and highly selective NK-2 receptor agonists.<sup>4</sup> The pyrrolo[3,4-*b*]pyrrole skeleton is also involved in uracil-based<sup>5</sup> and 4-oxo-4*H*-quinolizine<sup>6</sup> antibacterials. Two principally different strategies for the construction of the bicyclic pyrrolo[3,4-*b*]pyrrole core can be used. The first one makes use of the multistep synthesis of an acyclic or monocyclic precursor, followed by intramolecular cycloaddition<sup>3,7</sup> or cyclization.<sup>4,8</sup> The second approach, involving an intermolecular assembly of the pyrrolo[3,4-*b*]pyrrole backbone, was represented by Ru- or Mo-catalyzed cyclocarbonylation of  $\gamma$ -allenylhydrazones (Scheme 1, structure A).<sup>9</sup> In contrast to this reaction the convergent synthetic scheme, which ends with the intermolecular annulation of a pyrroline fragment to pyrrolidine ring, would permit rapid assemblage of the bicyclic pyrrolo[3,4-*b*]pyrrole core from rather simple starting materials if an appropriate C–C–N building block were found. One of the potential synthetic equivalents of a C–C–N synthon are 2*H*-

azirines, which have recently been widely used for heterocyclic synthesis<sup>10</sup> and have proven to be especially suitable for the preparation of pyrrole and 2-/3-pyrroline derivatives. Some of these reactions occur intermolecularly via the C=N bond cleavage of an azirine ring providing a C–C–N fragment for the targeted pyrrole or pyrroline system. Various compounds including enamines,<sup>11</sup> ynamines,<sup>12</sup> enols,<sup>13</sup> alkali metal enolates,<sup>14</sup> transition-metal enolates (Cu(I),<sup>15</sup> Cu(II),<sup>16,17</sup> Co(II),<sup>17</sup> Ni(II)<sup>18</sup>), pyridinium,<sup>19</sup> and imidazolium ylides<sup>20</sup> can be used in these annulations as the partners (C–C building blocks) of the azirines. However, only a few examples of the utilization of 2*H*-azirines for the synthesis of *ortho*-fused polycyclic systems via annulation are known.<sup>21</sup> Recently, we have found that 3-aryl-2*H*-azirines are capable of reacting with diazotetramic acids (3-diazopyrrolidine-2,4-diones) (Scheme 1, structure B) under Cu(acac)<sub>2</sub> catalysis to give 3a-(triazol-2-yl)pyrrolo[3,4-*b*]pyrroles as reaction products.<sup>22</sup>

We describe herein a facile and stereoselective approach to highly functionalized hexahydropyrrolo[3,4-*b*]pyrrole derivatives based on the Cu(I)-catalyzed (2 + 3)-annulation reaction of tetramic acids (Scheme 1, structure C) with 2*H*-azirines.


For the test experiments, we used readily available 3-phenyl-2*H*-azirine **2a** and tetramic acid **1a** (Table 1), which was synthesized from methyl *N*-(*p*-methoxybenzyl)glycinate and methyl phenylacetate. Heating a solution of compound **1a**, azirine **2a** (1.6 equiv), and 5 mol % of copper(II) acetylacetonate (calculated on tetramic acid) in 1,2-dichloroethane (DCE) gave a 1.8:1 mixture of adduct **3a** and bis(pyrrolidinedione) **4a** (Table 1, entry 1). Compound **3a** was isolated by column chromatography in 46% yield, while both diastereomers **4a**, originating from an oxidation of tetramic acid **1a**, were isolated in a further experiment (see Scheme 3, entry 9) and also fully characterized. Trace amounts of two dimerization products of azirine **2a**, 2-methyl-2,4-

**Scheme 1. Convergent Routes to Pyrrolo[3,4-*b*]pyrroles**



Received: June 30, 2015

Published: August 14, 2015

Table 1. Optimization of 3a Synthesis<sup>a</sup>

| entry | catalyst  | mol % | solvent | ratio 3a:4a <sup>b</sup> |
|-------|---|-------|---------|--------------------------|
| 1     | Cu(acac) <sub>2</sub>   | 5     | DCE     | 1.8:1 (46) <sup>c</sup>  |
| 2     | Cu(acac) <sub>2</sub>   | 5     | MeOH    | 2.4:1                    |
| 3     | CuI   | 5     | MeOH    | 0.5:1                    |
| 4     | [Cu(NCMe) <sub>4</sub> ][PF <sub>6</sub> ]                                  | 5     | MeOH    | 2.6:1                    |
| 5     | [Cu(NCMe) <sub>2</sub> (PPh <sub>3</sub> ) <sub>2</sub> ][BF <sub>4</sub> ] | 5     | MeOH    | 4.3:1                    |
| 6     | CuC $\equiv$ CPh  | 5     | MeOH    | 11:1 (72) <sup>c</sup>   |
| 7     | IPrCuCl   | 5     | MeOH    | 12:1 (84) <sup>c</sup>   |
| 8     | IPrCuCl   | 2.5   | MeOH    | 8.1:1                    |
| 9     | IPrCuCl   | 1     | MeOH    | 7.4:1                    |
| 10    | IPrCuCl   | 0.1   | MeOH    | 2.2:1                    |
| 11    | IPrCuCl   | 5     | MeOH    | 2.7:1 <sup>d</sup>       |


<sup>a</sup>Reaction conditions: **1a** (0.1 mmol), **2a** (0.16 mmol), a catalyst, solvent (1.5 mL), 10 min, 100 °C. <sup>b</sup>Ratio was determined by <sup>1</sup>H NMR spectroscopy. <sup>c</sup>Isolated yield of adduct **3a**. <sup>d</sup>60 °C, 50 min.

diphenyl-2*H*-imidazole and 2,5-diphenylpyrazine, were also isolated.<sup>23</sup>

In order to reduce the amount of side product **4a**, an optimization of reaction conditions was performed (Table 1). In the absence of a catalyst or in the presence of Rh<sub>2</sub>(OAc)<sub>4</sub> no reaction was observed. No traces of adduct **3a** were detected in the <sup>1</sup>H NMR spectra of the reaction mixtures obtained with the additives of Fe(III), Ni(II), and Co(III) acetylacetonates. It was also found that the catalysis with Cu(acac)<sub>2</sub> in methanol instead of DCE gives less side product **4a** (entry 2), and further optimization was carried out in this solvent. All of the tested copper(I) compounds showed catalytic activity (entries 3–7), with *N*-heterocyclic carbene–copper(I) complex (IPrCuCl) providing the best yield of **3a** and highest **3a:4a** ratio (entry 7). The low catalyst (IPrCuCl) loading as well as the decrease of the reaction temperature led to the increase of the side product quantity (entries 8–11). Thus, the optimal conditions were found to be the heating of a 1.6:1 mixture of azirine **2a** and tetramic acid **1a** in MeOH (concentration of **1a** 0.067 mol/L) at 100 °C in the presence of IPrCuCl (5 mol %).


With the optimized conditions in hand, we examined the scope of the reaction. The reaction of azirine **2b** with variously substituted tetramic acids **1a–m** provided pyrrolo[3,4-*b*]pyrroles **3b–n** in good to high yields (Scheme 2). 3-Aryl-, 3-hetaryl-, and 3-alkoxycarbonyl-substituted as well as *N*-unsubstituted, *N*-acetyl-, and *N*-phenyl-substituted tetramic acids are compatible with this transformation (entries 1–12). The reaction also proceeds well with fused tetramic acid **1m** giving rise to tricyclic pyrrolo[2,3-*a*]pyrrolizine derivative **3n**<sup>24</sup> (entry 13). Attempts, however, to accomplish the annulation of 3-unsubstituted **1n** and bulkier 5-phenyl-substituted tetramic acids **1o,p** failed (entry 14). The presence of an OH group in substrate **1** proved to be a necessary requisite for the reaction to occur, as no pyrrolo[3,4-*b*]pyrrole derivatives were obtained when *O*-methylated derivatives **1q,r** were used (entry 14).

It was also shown that 3-aryl-2*H*-azirines with electron-donating and electron-withdrawing substituents in the *para* position of the phenyl ring provide the corresponding

Scheme 2. Scope of Tetramic Acids **1a,b**

<sup>a</sup>Reaction conditions: **1** (0.2 mmol), **2b** (0.32 mmol), IPrCuCl (5 mol %), MeOH (3 mL). <sup>b</sup>Isolated yields. <sup>c</sup>Cu(acac)<sub>2</sub> (5 mol %) was used as a catalyst.

pyrrolo[3,4-*b*]pyrroles **3o–r** in good yields (Scheme 3, entries 1–4). In the reactions of 3-(*p*-nitrophenyl)-2*H*-azirine **2d** (entries 3 and 4), DCE was used as solvent because of the


Scheme 3. Scope of 2*H*-Azirines<sup>a,b</sup>

<sup>a</sup>Reaction conditions: **1** (0.2 mmol), **2** (0.32 mmol), IPrCuCl (5 mol %), solvent (3 mL). <sup>b</sup>Isolated yields. <sup>c</sup>DCE was used as a solvent. <sup>d</sup>**4b** was also isolated in 33% yield. <sup>e</sup>**4c** was also isolated in 20% yield. <sup>f</sup>**4a** was also isolated in 40% yield.

instability of the azirine in methanol under the reaction conditions. 2,3-Disubstituted azirines **2e,f** react slower and provide the annulation products **3t–v** in moderate yield (entries 6–8). Compounds **3t**,<sup>24</sup> **3u**,<sup>24</sup> and **3v** are formed stereoselectively as a single (3*RS*,3*aSR*)-isomer with *cis*-oriented substituents at the C3 and C3*a* positions. The use of the more hindered 2,2-dimethyl-3-phenyl-2*H*-azirine **2g** resulted in a lower yield of the desired product (entry 9) and an increase of the amount of side product **4a** (ratio **3w**:**4a** is 1:1.4 according to <sup>1</sup>H NMR). For the reactions with di- and trisubstituted azirines **2e–g** the presence of an aryl group at C3 of a tetramic acid seems to be crucial, as tetramic acids **1e,g–j,l** with an ester group at C3 did not give pyrrolo[3,4-*b*]pyrroles **3** at all.


Unexpectedly, tetramic acids **1a,b**, not containing at least one strong electron-withdrawing substituent at N1 or C3, react with 3-(*p*-nitrophenyl)-2*H*-azirine **2d** to give a diastereomeric mixture of aziridines **5a,b**,<sup>24</sup> but not the corresponding pyrrolo[3,4-*b*]pyrroles (Scheme 4). This reaction occurs under heating without a catalyst but slowly, providing lower yields of the desired product.

Scheme 4. Aziridine Formation



The reaction of the rather nucleophilic **1a,b** with highly electrophilic **2d** can be rationalized in terms of a nucleophilic addition over the C=N bond. Such additions are postulated for the Cu(II)- or Ni(II)-catalyzed reactions of azirines with acyclic 1,3-dicarbonyl compounds to produce pyrrole derivatives via the azirine N=C bond cleavage.<sup>17,18</sup> The results presented in Schemes 2 and 3 are in sharp contrast to the outcome of the above-mentioned reactions: under similar conditions, a cleavage of the azirine N–C2 single bond occurs. This unusual outcome, along with the fact that there is a formation of dimerization products **4**, has led us to the assumption that the formation of adducts **3** from tetramic acids **1** and 2*H*-azirine **2** proceeds via a radical pathway (Scheme 5).

Scheme 5. Proposed Reaction Mechanism



Cyclization of intermediate **8** gives a key cyclic radical intermediate **9**. This cyclization likely controls the stereochemical outcome of the reactions of 2,3-disubstituted azirines **2e,f** providing the sole stereoisomer of **3** (Scheme 3, entries 6–8). Finally, transformation of **9** to intermediate **10** and the release of the catalyst furnishes adduct **3**. The formation of the coupling product **4** can be rationalized in terms of the competing reaction of intermediate **8** with tetramic acid **1**, the formation of two radical species **11**, and subsequent dimerization. This undesirable route becomes dominant when sterically hindered azirines are used. It is worth noting that among the byproducts of the reaction acetophenones **12** were also detected, which have been previously reported as the products of an azirine radical decomposition.<sup>23</sup> The reason for the inability of some acyclic enols to react with azirines<sup>15–18</sup> via a radical pathway may be both the chelated structure of its metal enolates which are unable to provide intermediate **7** and the absence of additional radical-stabilizing substituent R<sup>3</sup> (Scheme 2).

We found that compound **1a** virtually did not oxidize into **4a** in MeOH when heated at 100 °C in the presence of IPrCuCl or Cu(acac)<sub>2</sub>, but an additive of sterically hindered 2,2-dimethyl-3-phenyl-2*H*-azirine (**2g**) strongly accelerates this process. It is noteworthy that oxidation of **1a** into **4a** under the action of 2,2-diphenyl-1-picrylhydrazyl radical at room temperature or molecular iodine under heating occurs very rapidly, but the addition of azirine **2a** to a mixture of **1a** and the radical initiator does not provide **3a**. From this result, it follows that the ordinary radical addition of species **11** to azirines **2** should be excluded from the sequence leading to pyrrolo[3,4-*b*]pyrroles **3**.

In conclusion, we have developed an effective method for the preparation of hexahydropyrrolo[3,4-*b*]pyrroles from easily accessible tetramic acids and 2*H*-azirines. The reaction is catalyzed both by Cu(I) and Cu(II) compounds, but the best results were obtained with the use of the imidazole-based NHC–Cu(I) complex. 3-Aryltetramic acids stereoselectively react with 2,3-disubstituted 2*H*-azirines, furnishing exclusively (3*RS*,3*aSR*)-isomer. The annulation of a new pyrroline ring proceeds via the N–C2 azirine bond cleavage, which can be explained by a free-radical reaction mechanism.

## ■ ASSOCIATED CONTENT

### Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.orglett.5b01883.

Experimental procedures, characterization data, X-ray structures, and <sup>1</sup>H, <sup>13</sup>C NMR spectra (PDF)

## ■ AUTHOR INFORMATION

### Corresponding Author

\*E-mail: m.s.novikov@chem.spbu.ru.

### Notes

The authors declare no competing financial interest.

## ■ ACKNOWLEDGMENTS

We gratefully acknowledge the financial support of the Russian Foundation for Basic Research (Grant Nos. 14-03-00187 and 14-03-31117) and Saint Petersburg State University (Grant Nos. 12.38.239.2014 and 12.38.217.2015). This research used

resources from the Magnetic Resonance Research Centre, Chemical Analysis and Materials Research Centre, Centre for X-ray Diffraction Studies, and Chemistry Educational Centre of Research Park of Saint Petersburg State University.

## REFERENCES

- (1) (a) Kaur, M.; Choi, D. H. *Chem. Soc. Rev.* **2015**, *44*, 58. (b) Bijleveld, J. C.; Gevaerts, V. S.; Di Nuzzo, D.; Turbiez, M.; Mathijssen, S. G. J.; de Leeuw, D. M.; Wienk, M. M.; Janssen, R. A. J. *Adv. Mater.* **2010**, *22*, E242. (c) Schrimpf, M. R.; Tietje, K. R.; Toupençe, R. B.; Ji, J.; Basha, A.; Bunnelle, W. H.; Daanen, J. F.; Pace, J. M.; Sippy, K. B. Patent WO0181347, 2001.
- (2) Russell, M. G. N.; Beer, M. S.; Stanton, J. A.; Sohal, B.; Mortishire Smith, R. J.; Castro, J. L. *Bioorg. Med. Chem. Lett.* **1999**, *9*, 2491.
- (3) Huck, B. R.; Llamas, L.; Robarge, M. J.; Dent, T. C.; Song, J.; Hodnick, W. F.; Crumrine, C.; Stricker-Krongrad, A.; Harrington, J.; Brunden, K. R.; Bennani, Y. L. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 2891.
- (4) Deal, M. J.; Hagan, R. M.; Ireland, S. J.; Jordan, C. C.; McElroy, A. B.; Porter, B.; Ross, B. C.; Stephens-Smith, M.; Ward, P. J. *Med. Chem.* **1992**, *35*, 4195.
- (5) Petersen, U.; Schenke, T.; Krebs, A.; Grohe, K.; Scheriewer, M.; Haller, I.; Mezger, K. G.; Endermann, R.; Zeiler, H. J. U.S. Patent 5 416 096, 1996.
- (6) Ma, Z.; Chu, D. T. W.; Cooper, C. S.; Li, Q.; Fung, A. K. L.; Wang, S.; Shen, L. L.; Flamm, R. K.; Nilius, A. M.; Alder, J. D.; Meulbroek, J. A.; Or, S. R. *J. Med. Chem.* **1999**, *42*, 4202.
- (7) (a) Henke, B. R.; Kouklis, A. J.; Heathcock, C. H. *J. Org. Chem.* **1992**, *57*, 7056. (b) Marx, M. A.; Grillot, A.-L.; Louer, C. T.; Beaver, K. A.; Bartlett, P. A. *J. Am. Chem. Soc.* **1997**, *119*, 6153. (c) Peng, G.; Sohn, A.; Gallop, M. A. *J. Org. Chem.* **1999**, *64*, 8342. (d) Pedrosa, R.; Andres, C.; de las Heras, L.; Nieto, J. *Org. Lett.* **2002**, *4*, 2513. (e) Garner, P.; Kaniskan, H. U. *Tetrahedron Lett.* **2005**, *46*, 5181. (f) Aurich, H. G.; Gentes, C.; Harms, K. *Tetrahedron* **1995**, *51*, 10497.
- (8) (a) Xu, Z.; De Moliner, F.; Cappelli, A. P.; Hulme, C. *Angew. Chem., Int. Ed.* **2012**, *51*, 8037. (b) Jeannotte, G.; Lubell, W. D. *J. Org. Chem.* **2004**, *69*, 4656. (c) Hogan, P. C.; Corey, E. J. *J. Am. Chem. Soc.* **2005**, *127*, 15386. (d) Rowley, M.; Leeson, P. D.; Williams, B. J.; Moore, K. W.; Baker, R. *Tetrahedron* **1992**, *48*, 3557.
- (9) (a) Kang, S.-K.; Kim, K.-J.; Hong, Y.-T. *Angew. Chem., Int. Ed.* **2002**, *41*, 1584. (b) Kim, S.-H.; Kang, E.; Yu, C.-M. *Synlett* **2007**, (15), 2439.
- (10) (a) Huang, C.-Y.; Doyle, A. G. *Chem. Rev.* **2014**, *114*, 8153. (b) Khlebnikov, A. F.; Novikov, M. S. *Tetrahedron* **2013**, *69*, 3363.
- (11) (a) Auricchio, S.; Bini, A.; Pastormerlo, E.; Truscello, A. M. *Tetrahedron* **1997**, *53*, 10911. (b) Auricchio, S.; Truscello, A. M.; Lauria, M.; Meille, S. V. *Tetrahedron* **2012**, *68*, 7441.
- (12) Zhu, L.; Yu, Y.; Mao, Z.; Huang, X. *Org. Lett.* **2015**, *17*, 30.
- (13) Alves, M. J.; Gilchrist, T. L.; Sousa, J. H. *J. Chem. Soc., Perkin Trans. 1* **1999**, *21*, 1305.
- (14) (a) Palacios, F.; Ochoa de Retana, A. M.; Vélez del Burgo, A. J. *Org. Chem.* **2011**, *76*, 9472. (b) Ben Cheikh, R.; Bouzouita, N.; Ghabi, H.; Chaabouni, R. *Tetrahedron* **1990**, *46*, 5155. (c) Laurent, A.; Mison, P.; Nafti, A.; Pellissier, N. *Tetrahedron Lett.* **1982**, *23*, 655.
- (15) Li, T.; Xin, X.; Wang, C.; Wang, D.; Wu, F.; Li, X.; Wan, B. *Org. Lett.* **2014**, *16*, 4806.
- (16) Chiba, S.; Wang, Y.-F.; Lapointe, G.; Narasaka, K. *Org. Lett.* **2008**, *10*, 313.
- (17) Galenko, A. V.; Khlebnikov, A. F.; Novikov, M. S.; Avdontceva, M. S. *Tetrahedron* **2015**, *71*, 1940.
- (18) (a) Galenko, E. E.; Galenko, A. V.; Khlebnikov, A. F.; Novikov, M. S. *RSC Adv.* **2015**, *5*, 18172. (b) Dos Santos Filho, P. F.; Schuchardt, U. *Angew. Chem., Int. Ed. Engl.* **1977**, *16*, 647.
- (19) Khlebnikov, A. F.; Golovkina, M. V.; Novikov, M. S.; Yufit, D. S. *Org. Lett.* **2012**, *14*, 3768.
- (20) Khlebnikov, A. F.; Tomashenko, O. A.; Funt, L. D.; Novikov, M. S. *Org. Biomol. Chem.* **2014**, *12*, 6598.
- (21) (a) Mei, Y.; Bentley, P. A.; Wang, W. *Tetrahedron Lett.* **2006**, *47*, 2447. (b) Candito, D. A.; Lautens, M. *Org. Lett.* **2010**, *12*, 3312.
- (c) Dähler, M.; Prewo, R.; Bieri, J. H.; Heimgartner, H. *Helv. Chim. Acta* **1983**, *66*, 1456. (d) Schläpfer-Dähler, M.; Heimgartner, H. *Helv. Chim. Acta* **1993**, *76*, 2321.
- (22) Rostovskii, N. V.; Novikov, M. S.; Khlebnikov, A. F.; Korneev, S. M.; Yufit, D. S. *Org. Biomol. Chem.* **2013**, *11*, 5535.
- (23) Auricchio, S.; Grassi, S.; Malpezzi, L.; Sartori, A. S.; Truscello, A. M. *Eur. J. Org. Chem.* **2001**, *2001*, 1183.
- (24) CCDC 1061210 (**3f**), CCDC 1061136 ((**3aRS,8aSR,8bSR**)-**3n**), CCDC 1061124 (**3o**), CCDC 1061125 (**3t**), CCDC 1407546 (**3u**), and CCDC 1061137 ((**RS,SR**)-**5b**) contain the supplementary crystallographic data for this paper. These data can be obtained free of charge from the Cambridge Crystallographic Data Centre via [www.ccdc.cam.ac.uk/data\\_request/cif](http://www.ccdc.cam.ac.uk/data_request/cif).